Geerts S, Bruynooghe F, De Cuyper H, Demeulemeester F, Haazen L
Department of Psychiatry, St. Lucas General Hospital, Bruges, Belgium.
Clin Neuropharmacol. 1994;17 Suppl 1:S50-7. doi: 10.1097/00002826-199417001-00007.
The efficacy and tolerability of moclobemide (300 or 600 mg daily) and fluoxetine (20 or 40 mg daily) were compared in a 6-week, double-blind study of 25 inpatients and 24 outpatients who had major depressive episodes without psychotic features (DSM-III-R). Although the clinical results of this study suggest better efficacy with moclobemide and better tolerability with fluoxetine, a statistically significant difference between treatment groups was noted only with respect to Clinical Global Impressions recorded after 10 days of therapy; these were significantly better in the moclobemide group. A daily dosage of 300 mg of moclobemide and 20 mg of fluoxetine would thus appear to be comparable both in antidepressant efficacy and tolerability.
在一项针对25名住院患者和24名门诊患者的为期6周的双盲研究中，比较了吗氯贝胺（每日300或600毫克）和氟西汀（每日20或40毫克）的疗效和耐受性，这些患者均患有无精神病性特征的重度抑郁发作（DSM-III-R）。尽管该研究的临床结果表明吗氯贝胺疗效更佳，氟西汀耐受性更佳，但仅在治疗10天后记录的临床总体印象方面，治疗组之间存在统计学上的显著差异；吗氯贝胺组的这些结果明显更好。因此，每日300毫克的吗氯贝胺和20毫克的氟西汀在抗抑郁疗效和耐受性方面似乎相当。
